Medsafe New Zealand Medical Device Registration
Last reviewed:
Plan New Zealand medical device access through the applicable Medsafe pathway, with local responsibilities, product evidence, labeling and lifecycle controls defined before launch.
New Zealand medical device regulatory framework
New Zealand medical device regulatory framework
New Zealand is different from many medical device markets because most devices are not approved by Medsafe before supply. Instead, New Zealand relies on sponsor notification through the Web Assisted Notification of Devices database, known as WAND, plus sponsor-held evidence and post-market oversight.
This lighter pathway can be commercially attractive, but it should not be treated as a no-regulation market. The New Zealand sponsor must understand the device, notify WAND within the required timeframe, keep evidence that the product is safe for its intended purpose, maintain product and supplier records, and support complaint, adverse event, recall, and change obligations.
For foreign manufacturers, the first decision is therefore operational: who is the New Zealand sponsor, what evidence will that sponsor hold, and how will post-market responsibilities be managed after launch?
Authority and WAND notification
Medsafe is New Zealand's medicines and medical devices safety authority. The WAND database records medical devices supplied in New Zealand. WAND notification is important, but it is not the same as pre-market approval, certification, or product endorsement by Medsafe.
The sponsor is the New Zealand person or company that imports or supplies the device. The sponsor must notify WAND within the required timeframe after becoming the sponsor of the device, described in Medsafe sponsor guidance as 30 calendar days. The sponsor also needs to maintain information about the device, manufacturer, classification, GMDN, intended purpose, and supply model. There is no government fee for WAND notification and no renewal cycle: a WAND entry stays active until the sponsor ceases supply, but the sponsor must correct or remove outdated information within 10 working days.
Because the WAND entry does not prove regulatory approval, manufacturers should avoid promotional language suggesting that a device is "approved by Medsafe" merely because it has been notified. The safer framing is that the device has been notified in WAND by the New Zealand sponsor.
Classification and evidence expectations
New Zealand WAND notification requires enough product information to identify the device and support the sponsor's obligations. Manufacturers should confirm the product's device status, intended purpose, GMDN selection, risk classification, manufacturer details, and product family structure before notification.
Even where Medsafe does not perform pre-market review, the sponsor should hold evidence that the product is safe for its intended purpose. That evidence may include conformity assessment documents, ISO 13485 certificates, EU CE or MDR/IVDR evidence, Australian TGA evidence, US FDA evidence, test reports, risk management, clinical or performance evidence, labeling, IFU, and post-market procedures. The right package depends on device type and risk.
For manufacturers selling in both Australia and New Zealand, there can be practical reuse of technical documentation and quality evidence. Reuse is helpful, but the New Zealand sponsor still needs a New Zealand-specific WAND record, product information, and post-market responsibility model.
Sponsor and labeling responsibilities
The sponsor role should be selected carefully. It may be a distributor, importer, affiliate, or regulatory partner. The sponsor's responsibilities can affect who controls WAND entries, who receives Medsafe communications, who holds evidence, who manages complaints, and who coordinates recalls.
Labeling should be reviewed before supply to make sure the product identity, intended use, warnings, storage conditions, batch or serial controls, manufacturer information, and local sponsor or importer details are consistent with the device being notified. If a device is supplied with digital labeling, software instructions, or online IFU content, those materials should be included in the evidence review.
Post-market obligations
Post-market control is the center of the New Zealand system. Sponsors and manufacturers should maintain procedures for complaints, adverse events, field safety corrective actions, recalls, distribution records, changes, and regulator communications. Global complaint handling should be mapped to New Zealand escalation rules so that local obligations are not missed.
Changes can also affect WAND information. Product name changes, manufacturer changes, model changes, intended-purpose changes, sponsor changes, or supply model changes should be reviewed before implementation. If the product is software-driven, update governance should include regulatory impact assessment for changes to intended use, algorithm behavior, cybersecurity, performance, or labeling.
Practical launch checklist
A practical New Zealand launch plan should include seven workstreams:
- Confirm medical-device status, intended purpose, classification, and GMDN selection.
- Select the New Zealand sponsor and define who owns WAND notification and maintenance.
- Prepare WAND product, manufacturer, model, classification, and sponsor information.
- Confirm that the sponsor holds adequate technical, quality, labeling, and safety evidence.
- Review labeling, IFU, sponsor/importer details, software information, and product claims.
- Build complaint, adverse event, recall, distribution-record, and change-control procedures.
- Coordinate New Zealand planning with Australia, Singapore, and other Asia Pacific launches where evidence can be reused.
Pure Global supports manufacturers with New Zealand WAND notification planning, sponsor-role coordination, evidence review, labeling checks, pricing visibility, and post-market compliance.
New Zealand pathway and evidence decisions
| Workstream | Local requirement or decision |
|---|---|
| WAND entry | Notification, not premarket product approval |
| Sponsor | New Zealand person/company with the relevant supply role |
| Evidence | Sponsor holds adequate safety and intended-purpose support |
| Updates | Correct changed/incomplete information within the applicable 10-working-day rule |
WAND notification does not permit claims of “Medsafe approved.” Medsafe’s WAND overview states a 30-calendar-day notification timeframe; plan promptly and use the earlier calendar deadline when legacy process pages describe working days. Confirm special categories and exemptions rather than assuming every IVD or research item has the same notification treatment.
Use the official Medsafe instructions and related official process guidance for the filing scope. Maintain a controlled record of the chosen route, current evidence, open gaps, responsible parties and authority responses. Separate fees, document preparation, review and applicant work when planning the launch.
For a multi-country program, use the market directory to coordinate evidence reuse while retaining the local applicant, language, registration and postmarket requirements for each destination.
Regulatory Update · Nov 6, 2026Thai device change timelinesRegulatory Update · Nov 1, 2026Hong Kong MDACS Recognised StandardsRegulatory Update · Oct 27, 2026Pakistan DRAP PSW Device Import RulesRegulatory Update · Oct 20, 2026Singapore HSA Integration and HTA ScopeCase Study · Aug 5, 2026Vietnam IVD Registration for an Oncology AssayBlog · Nov 9, 2026Classification across four marketsBlog · Nov 2, 2026Five-market device change controlBlog · Oct 5, 2026China GMP inspection preparationBlog · Sep 6, 2026One Device, Three UDI DatabasesVideo · Oct 16, 2026South Korea MFDS: Device RegistrationUse the lighter WAND pathway without underbuilding compliance.
We provide turnkey New Zealand medical device regulatory support, all for a flat annual fee:
Device qualification, classification, GMDN, and WAND notification planning before first supply.
New Zealand sponsor-role coordination, evidence checks, and product information setup.
Labeling, IFU, importer, distributor, and technical documentation gap review.
Post-market support for changes, complaints, adverse events, recalls, and Medsafe communications.
Frequently asked questions
No. WAND is a notification database, and inclusion must not be promoted as a Medsafe safety or suitability endorsement. The sponsor must still hold evidence and meet ongoing obligations.
No. The New Zealand sponsor and WAND record are separate from Australian ARTG arrangements. One service group may support both, but local roles, records and reporting responsibilities must be defined.
No. The sponsor should hold appropriate evidence supporting safety and intended purpose and be able to respond to Medsafe. Maintain complaints, recalls, changes and accurate database information.
Single Process,
Multiple Markets
When you partner with Pure Global, a single registration process opens doors to multiple countries. Our global subsidiaries make this streamlined path possible.
Let's Talk,
Anywhere You Are.
Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.
Contact us